Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salmonella polysaccharide-Pfs230 conjugate vaccine
- Development stage
- Preclinical
- Lead developer
- International Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Salmonella polysaccharide-Pfs230 conjugate vaccine is a dual-target glycoconjugate vaccine candidate in preclinical development by the International Vaccine Institute (IVI) and the National Institutes of Health (NIH). It is designed to protect against both malaria transmission and invasive non-typhoidal Salmonella (iNTS) infections, which are co-endemic in regions like sub-Saharan Africa. The vaccine consists of Salmonella O-specific polysaccharides (OSP) from Salmonella Typhimurium and Salmonella Enteritidis chemically conjugated to the Plasmodium falciparum transmission-blocking antigen Pfs230 (specifically the Pfs230D1 domain). In this conjugate, Pfs230 acts as both a carrier protein to enhance the immunogenicity of the T-cell-independent Salmonella polysaccharides and as an antigen to elicit transmission-blocking antibodies against malaria.
- Other names
- Salmonella polysaccharide-malaria antigen conjugate vaccineiNTS polysaccharide-Pfs230 conjugate vaccineiNTS-Pfs230 conjugate vaccineiNTS-Pfs-230 conjugate vaccineiNTS-Pfs 230 conjugate vaccine
02
Targets
Pfs230
Beyond the preview
Go deeper on Salmonella polysaccharide-Pfs230 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salmonella polysaccharide-Pfs230 conjugate vaccine.